The CSIR states that there are no benefits to coffee enemas
On Monday morning, Pfizer announced it will be abandoning the development of its GLP-1 drug danuglipron, which was being investigated for chronic weight management
A similar conversation is now emerging around obesity medicines: GLP-1 and dual agonists are being recognised internationally as evidence-based treatments for obesity with cardiometabolic benefit.[8] Indian insurers may progressively consider coverage when obesity is severe and linked with diabetes, heart disease, or sleep apnoea, rather than for cosmetic weight loss alone.[10] For families, this could mean negotiating group policies and reading the policy wording carefully to see if medically supervised GLP-1 therapy for obesity-with-complications is covered
Welchol is not for everyone, especially those with: Tell your health care provider (HCP) if you have high triglycerides (greater than 300 mg/dL)
The warning letters sent to manufacturers of the products note that HCG has not received FDA approval for any weight loss indication
The Motley Fool has positions in and recommends Amgen and Merck